JD-5037
Modify Date: 2025-08-25 13:09:51
JD-5037 structure
|
Common Name | JD-5037 | ||
|---|---|---|---|---|
| CAS Number | 1392116-14-1 | Molecular Weight | 572.506 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 731.3±70.0 °C at 760 mmHg | |
| Molecular Formula | C27H27Cl2N5O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 396.1±35.7 °C | |
Use of JD-5037JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. |
| Name | JD5037 |
|---|---|
| Synonym | More Synonyms |
| Description | JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.5 nM (CB1R)[1] |
| In Vivo | JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice[2]. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice[3]. |
| Animal Admin | Mice: JD-5037 is formulated in vehicle (V; 1% Tween80, 4% DMSO, 95% Saline). Obese mice are treated chronically (28 d) with vehicle (V; 1% Tween80, 4% DMSO, 95% Saline), JD5037, or SLV319 at a dose of 3 mg/kg, i.p. Body weight and food intake are monitored daily. Mice are euthanized by cervical dislocation under anesthesia; the brain, hypothalamus, liver, and combined fat pads are removed, weighed, and snap-frozen, and trunk blood is collected for determining the endocrine and biochemical parameters[2]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 731.3±70.0 °C at 760 mmHg |
| Molecular Formula | C27H27Cl2N5O3S |
| Molecular Weight | 572.506 |
| Flash Point | 396.1±35.7 °C |
| Exact Mass | 571.121155 |
| LogP | 4.58 |
| Vapour Pressure | 0.0±2.4 mmHg at 25°C |
| Index of Refraction | 1.662 |
| Storage condition | 2-8℃ |
| (E)-N-([(4S)-3-(4-Chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl]{[(4-chlorophenyl)sulfonyl]amino}methylene)-L-valinamide |
| JD5037 |
| Butanamide, 2-[[(E)-[(4S)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazol-1-yl][[(4-chlorophenyl)sulfonyl]imino]methyl]amino]-3-methyl-, (2S)- |
| JD-5037 |